NRX Pharmaceuticals (NRXP) Stock
What NRX Pharmaceuticals's price implies, from its SEC filings.
Key numbers
- P/E (forward)
- -6.80x
- Operating margin
- -586.2%
What NRX Pharmaceuticals's price implies
NRX Pharmaceuticals's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.
Revenue and free cash flow
Fiscal years, from NRX Pharmaceuticals's 10-K filings.
NRX Pharmaceuticals revenue and free cash flow
FY2018–FY2025Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $1M |
| Net income | -$93M | -$40M | -$30M | -$25M | -$29M |
| Free cash flow | -$38M | -$40M | -$22M | -$11M | — |
| EPS (diluted) | -$19.80 | -$6.00 | -$3.98 | -$2.36 | -$1.34 |
| Operating margin | — | — | — | — | -1,324.4% |
Superinvestors who own NRXP
From each investor's latest 13F filing (what a 13F shows). All 3 holders
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Paul Marshall Marshall Wace | New position | $795,831 | 0.00% | Q2 2026 |
| Jim Simons Renaissance Technologies | New position | $157,874 | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments | New position | $108,095 | 0.0% | Q2 2026 |
NRX Pharmaceuticals insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of NRXP in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from NRXP's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How NRX Pharmaceuticals compares
NRX Pharmaceuticals's operating margin is higher than 11% of Healthcare companies and 4% of the 2,820 companies with an operating margin figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Operating margin | 11% | 4% |
Questions about NRX Pharmaceuticals
Are NRX Pharmaceuticals insiders buying the stock?
No open-market insider purchases of NRXP in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own NRX Pharmaceuticals?
3 of the superinvestors Investingly tracks hold NRXP in their latest 13F, including Paul Marshall, Jim Simons, Two Sigma.
Companies like NRX Pharmaceuticals
NovaBridge Biosciences (NBP)$102MTuHURA Biosciences Inc (HURA)$104MInovio Pharmaceuticals Inc (INO)$100MImmunic Inc (IMUX)$106MAnavex Life Sciences Corp (AVXL)$107MCellectis SA (CLLS)$107MFoghorn Therapeutics Inc (FHTX)$110MLENZ Therapeutics Inc (LENZ)$110MAnixa Biosciences Inc (ANIX)$110M All Healthcare stocks→Prices and ratios as of Nov 9, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.